Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial
00

Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial

Sep 22, 2026

Otsuka Pharmaceutical and Ionis Pharmaceuticals announce that their experimental drug ulefnersen met its primary endpoint in the Phase 3 FUSION trial. Involving 73 patients with FUS-ALS, a rare and rapidly progressive genetic form of ALS, the trial demonstrates statistically significant improvements in function and survival compared to placebo (p=0.0005). The partners plan to discuss expedited regulatory approval pathways with the FDA.

Phase 3 FUSION trial results

  • ▪The Phase 3 FUSION trial of ulefnersen met its primary endpoint in 73 FUS-ALS patients, yielding a p-value of 0.0005 and demonstrating statistically significant improvements in function and survival compared to placebo.
  • ▪The Phase 3 FUSION trial of ulefnersen met several secondary endpoints, including reducing serum neurofilament light chain levels and delaying time to death, permanent ventilation, rescue, or disease-related withdrawal.

Regulatory and access plans for ulefnersen

  • ▪Otsuka Pharmaceutical launched a global early access program allowing physicians to request ulefnersen for eligible FUS-ALS patients who are unable to participate in clinical trials prior to regulatory approval.
  • ▪Otsuka Pharmaceutical plans to discuss the Phase 3 FUSION trial results with the U.S. Food and Drug Administration and other global health authorities to explore potential expedited regulatory approval pathways for ulefnersen.

Ulefnersen and Ionis' ALS portfolio

  • ▪Ulefnersen expands Ionis Pharmaceuticals' genetic amyotrophic lateral sclerosis portfolio, which also includes Qalsody, an FDA-approved drug targeting SOD1-related ALS developed in partnership with Biogen.
  • ▪Ulefnersen is an experimental antisense oligonucleotide medicine designed to target the genetic cause of FUS-ALS by reducing the production of the disease-linked fused in sarcoma protein.

Characteristics of FUS-ALS

  • ▪FUS-ALS is a rare, rapidly progressive, and fatal genetic form of amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene, accounting for an estimated 0.6% of all ALS cases.
  • ▪Mutations in the fused in sarcoma gene are highly prevalent in juvenile and pediatric amyotrophic lateral sclerosis, accounting for an estimated 43% to 52% of those cases.

Otsuka and Ionis licensing agreement

  • ▪Under the 2024 licensing agreement, Ionis Pharmaceuticals remains eligible to receive regulatory and commercial milestone payments as well as tiered royalties on future net sales of ulefnersen.
  • ▪Otsuka Pharmaceutical acquired exclusive global rights to ulefnersen from Ionis Pharmaceuticals in November 2024, paying an upfront fee of $10 million.

Debatable claims

  • ▪Otsuka's early access program for ulefnersen is justified before regulatory approval
  • ▪The FDA should grant expedited approval to ulefnersen for FUS-ALS

6 sources

Blockonomi
Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results
View source article
Reuters
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study | Reuters
View source article
Investing
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data By Investing.com
View source article
Endpoints
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal
View source article
Biopharmadive
Roche, Ionis RNA drug scores in kidney disease study
View source article

Story comments

Loading comments…

Topics

Drug Policy, Pricing & ApprovalRare genetic diseasesClinical trial endpointsClinical Trial Design & EvaluationClinical trialsDrug Approval and Clinical Trials